United Therapeutics Board Authorizes New $2.0 Billion Share Repurchase Program

Executive Summary

On October 21, 2026, the Board of Directors of United Therapeutics Corporation (Nasdaq: UTHR) authorized a substantial new share repurchase program permitting the repurchase of up to $2.0 billion of the company's common stock over a one-year period concluding on October 21, 2027.

Key Highlights

• Authorization Amount: Up to $2.0 billion of common stock, par value $0.01 per share.
• Term: 12 months, expiring on October 21, 2027.
• Implementation Flexibility: Purchases may occur via accelerated share repurchase (ASR) agreements, open market transactions, privately negotiated transactions, or other mechanisms subject to market conditions and liquidity.
• Existing Buyback Status: The company currently has an ongoing ASR initiated in September 2026 under a prior authorization set to terminate in Q4 2026; this new $2.0B capacity is separate and will not be reduced by the completion of that ongoing program.

Market & Trading Implications

A $2.0 billion buyback represents a major capital return initiative, signaling executive and board confidence in United Therapeutics' balance sheet strength, free cash flow generation, and long-term valuation.